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The Ussing chamber technique has contributed significantly to our understanding of the role of ion transport in the pathogenesis of human
diseases like cystic fibrosis (CF). Here, we summarize protocols developed to study the Cl channel function of the cystic fibrosis
transmembrane conductance regulator (CFTR) protein in rectal biopsies from normal individuals and CF patients. These protocols can be
applied to study the function and pharmacological modulation of wild-type and mutant CFTR in the context of the native epithelium.
Together with sweat testing and genetic analyses, these functional measurements may aid in establishing a diagnosis of CF.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; CFTR; CF diagnosis; Human colon; Ion transport1. Introduction
Cystic fibrosis (CF) is caused by more than 1000 mutations
in the CFTR gene. The CFTR protein acts as a cAMP-
dependent Cl channel and as a regulator of other epithelial
ion channels. In the past 15 years, several research groups
developed modified Ussing chambers to study the CF ion
transport defect in freshly excised native tissues [1–3]. More
recently, we have developed a perfusedmicro-Ussing chamber
that accommodates small human tissue specimens [4]. Con-
tinuous perfusion of the tissues allows paired testing of the
effects of different drugs in the absence and presence of CFTR
activation in the same tissue. This configuration increases the
degree of freedom in determining the efficacy of pharmaco-
logical modalities in native human tissues. We have used this
approach to study different aspects of the regulation/pharma-1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.035
Abbreviations: CaCC, Ca2+-activated Cl channel; CCH, carbachol;
ENaC, epithelial Na+ channel; IBMX, isobutylmethylxanthine; Isc, short-
circuit current; PE, polyethylene; PG, prostaglandin; Rte, transepithelial
resistance; Vte, transepithelial voltage.
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E-mail address: mmall@med.unc.edu (M. Mall).cological modulation of ion transport and CF pathophysiology
in native human airway and colonic tissues [4–9]. The
standardized experimental protocol outlined here focuses on
functional detection of CFTR and characteristic alterations of
ion transport properties in CF rectal epithelia. Compared to
native human airway tissue, rectal epithelium is easily acces-
sible at any age, expresses relatively high levels of CFTR and
does not undergo tissue destruction/remodelling in CF. Char-
acteristic alterations of bioelectric responses in CF rectal
epithelia include enhanced amiloride-sensitive Na+ transport,
defective cAMP-dependent Cl secretion and defective cho-
linergic Cl secretion. Thus bioelectricmeasurements on rectal
epithelia can be applied as a functional diagnostic tool to aid in
establishing a diagnosis of CF, if sweat test results are
equivocal and/or if disease-causing CFTR mutations are not
readily identified by DNA mutation analysis.2. General overview of the protocol
2.1. Materials and methods
2.1.1. Ussing chambers
We use continuously perfused micro-Ussing chambers
that were developed for bioelectric measurements oned by Elsevier B.V. All rights reserved.
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two half-chambers, each with a volume of f 1 ml. The
tissue is mounted onto a removable disk with an open
area of f 0.95 mm2 and is sandwiched between the
two half-chambers. (Additional information on chamber
design and technical details is given in Refs. [10,11].)
The experimental solution perfusing the luminal and
basolateral surfaces of the tissues are delivered from
reservoirs above the chamber via polyethylene (PE)
tubing. Continuous bilateral perfusion of tissues allows
rapid onset of drug effects as well as efficient wash out.
The temperature of the experimental solution is main-
tained at 37 jC by a water jacket and a heated
chamber socket connected to a thermostat-heating bath.
Electrodes for recordings of transepithelial voltage (Vte)
and for pulsed current injection are interfaced with a
differential amplifier and pulse generator. Data are
output from the amplifier to a chart recorder or a data
acquisition system interfaced with a PC. (A detailed
description of experimental solutions is given in Refs.
[6,11]).
2.1.2. Rectal biopsies (tissue collection and mounting)
Small superficial rectal biopsies (f 2–3 mm in diame-
ter) are obtained by rectoscopy and forceps biopsy. Biopsy
specimens are immediately stored in an ice cold buffer
solution [11] and mounted on a circular disk with a central
convex open area of f 0.95 mm2. Mounting of tissues is
performed under a stereomicroscope using dissection for-
ceps. Once the tissues are mounted on the disk, the
preparation is sandwiched between the two half-cells of
the Ussing chambers.
2.1.3. Using chamber experiments
Transepithelial measurements are performed under
open-circuit conditions [12]. Before tissues are mounted,
chambers are equilibrated at 37 jC to ensure that Vte
electrodes are stable. Next, Vte is set to zero and the fluid
resistance of the empty chambers is noted. After mounting
of rectal tissues in Ussing chambers, an equilibration
period of z 40 min is allowed for stabilization of basal
Vte and transepithelial resistance (Rte). The luminal and
basolateral surfaces of the epithelium are continuously
perfused with experimental solution allowing the compar-
ison of the effects of pharmacological compounds (e.g.,
cholinergic agonists) in the absence and presence of
cAMP-dependent stimulation (i.e., CFTR activation) in
the same tissue. Rte is determined by applying short (1 s)
intermittent current pulses (DI = 0.5 AA), and the
corresponding changes in Vte (DVte), as well as basal Vte
are recorded continuously during the course of the exper-
iment. Values for the Vte are referred to the serosal side of
the epithelium. Rte is calculated according to Ohms law
(Rte =DVte/DI) and corrected for fluid resistance. The
equivalent short circuit current (Isc) is determined from
Vte and Rte, i.e., Isc =Vte/Rte [12].2.2. Experimental protocol
2.2.1. Background
The CFTR protein acts as a cAMP-dependent Cl
channel in the luminal membrane of colonic epithelia.
Previous studies demonstrated that cAMP-mediated and
Ca2 +-dependent agonists act co-operatively to determine
the magnitude of colonic Cl secretion (for review, see
Ref. [8]). Our initial studies showed that Ca2 +-activated
Cl secretion (e.g., by cholinergic activation) in human
colonic epithelium depends on functional CFTR, rather
than Ca2 +-activated alternative Cl channels (CaCC). This
was demonstrated by data showing (i) that basal and
cholinergic Cl secretion in non-CF tissues is inhibited
by the cyclooxygenase inhibitor indomethacin (which
inhibits production of prostaglandins (PG) that act as major
agonists of the cAMP-dependent pathway in the colonic
epithelium); (ii) that Ca2 +-dependent Cl secretion is
augmented after pre-stimulation with cAMP-dependent
agonists; and (iii) that both cAMP-dependent and Ca2 +-
activated Cl secretion is defective in CF rectal tissues
[4,6,8,13]. Data derived from these studies support the
concept that colonic Cl secretion requires functional
CFTR in the luminal membrane, and that Ca2 +-dependent
stimulation induces activation of basolateral K+ channels
that increase the driving force for luminal CFTR-mediated
Cl secretion. Based on these studies, we developed a
standardized protocol to assess CFTR function in human
rectal biopsies.
2.2.2. Standardized experimental protocol
This standardized protocol for assessment of CFTR
function in human intestinal tissues is summarized in Table
1, including the sequence in which drugs are added, typical
findings in non-CF tissues and characteristic alterations of
ion transport observed in CF rectal epithelia. Fig. 1 shows
characteristic responses to cholinergic and cAMP-dependent
activation in non-CF and CF rectal tissues and Table 2 lists
mean values for bioelectric responses as determined from
previous studies [5,6].
2.2.3. Data interpretation and characteristic alterations of
ion transport in CF rectal tissues
As outlined above, basal, cAMP-dependent and cholin-
ergic Cl secretion in human rectal tissues depend on
functional CFTR. Under basal conditions, CFTR may be
activated to a variable degree by release of endogenous
mediators (e.g., PGE2). Due to variable levels of these
mediators, the responses induced by cAMP-dependent or
cholinergic activation under basal conditions may vary
widely, and cholinergic responses may range from a
lumen-negative Cl secretory response to a biphasic pos-
itive/negative response to a lumen-positive K+ secretory
response [4,6,8]. Therefore, intracellular cAMP levels have
to be controlled prior to use of cAMP-dependent and
cholinergic responses for quantitative assessment of CFTR
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Table 1
Standardized protocol to assess CFTR function in human rectal biopsies
Compound
(concentration,
compartment)
Effects and characteristic responses in normal vs.
CF tissues (references)
I Amiloride1
(10 Amol/l, lu)
Inhibition of electrogenic Na+ absorption by
inhibition of the amiloride-sensitive epithelial Na+
channel (ENaC). Amiloride-sensitive Na+
transport is increased in CF rectal biopsies [5].
II CCH2
(100 Amol/l, bl)
washout
Activation of cholinergic (Ca2 +-activated)
secretion under basal conditions. CCH typically
induces Cl secretory responses (lumen-negative)
in normal tissues, and inverse K+ secretory
responses (lumen-positive) in CF tissues.
However, likely due to low endogenous PG levels,
lumen-positive responses are observed in f 20–
30% of normal tissues [6].
III Indomethacin1
(10 Amol/l, bl)
Inhibition of basal cAMP-dependent Cl secretion
by inhibition of PG formation in native tissues. In
normal tissues, basal Cl secretion is largely
inhibited by indomethacin treatment (40–60 min).
CF tissues lack basal Cl secretion [4,6].
IV CCH2
(100 Amol/l, bl)
washout
Activation of cholinergic (Ca2 +-activated)
secretion in the presence of indomethacin. After
indomethacin pre-treatment (i.e., CFTR
inhibition), CCH induces K+ secretion
(lumen-positive) in normal and CF tissues. Due to
the overlap of bioelectric responses in normal and
CF, assessment of cholinergic responses is not
reliable to discriminate between normal and CF
under these experimental conditions [6,8].
V IBMX/forskolin1
(100/1 Amol/l, bl)
Activation of cAMP-dependent (CFTR-mediated)
secretion. cAMP-dependent activation induces
sustained Cl secretory responses in normal, but
not in CF tissues [4,6,8].
VI CCH2
(100 Amol/l, bl)
washout
Activation of cholinergic (Ca2 +-activated)
secretion in the presence of IBMX/forskolin.
Cholinergic co-activation further increases Cl
secretion in normal tissues, and induces an inverse
K+ secretory response in CF tissues [4,6,8].
VII Bumetanide1
(50 Amol/l, bl)
Inhibition of transepithelial Cl secretion by
inhibition of the Na+–K+–2Cl co-transporter
(NKCC1). Due to the lack of potent, specific
CFTR Cl channel blockers, bumetanide is
applied to test for transepithelial Cl secretion [6].
(I –VII) Sequence of application of pharmacological compounds in Using
chamber experiments: 1Amiloride, indomethacin, IBMX/forskolin, and
bumetanide are added as indicated, and continously present in the bath
solution thereafter. 2CCH is added under basal conditions (II), and after pre-
treatment with indomethacin (IV) and IBMX/forskolin (VI). The CCH-
induced responses (peak and plateau responses) are recorded under these
different experimental conditions (i.e., absence and presence of cAMP-
dependent stimulation). Each application of CCH is followed by a 20–30-
minwashout period.Abbreviations: lu = luminal, bl = basolateral application.
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inhibition of endogenous PG formation by 60 min pre-
treatment with indomethacin. Under these experimental
conditions, we use cAMP-mediated Cl secretion as the
primary readout for CFTR function. In normal tissues,
cAMP-dependent activation with isobutylmethylxanthine
(IBMX)/forskolin induces large Cl secretory responses
that are absent in CF patients (Table 2, Fig. 1). As
summarized in Table 2, besides defective cAMP-dependentCl secretion, other hallmarks of abnormal ion transport
across rectal epithelia of CF patients include enhanced
amiloride-sensitive Na+ transport, defective cholinergic
Cl secretion in the presence of cAMP activation, and
detection of K+ secretion in the absence and presence of
cAMP activation. These features are indicative of CF and
thus bioelectric measurements on rectal biopsies can be
applied as a functional diagnostic test for CF. Further
studies are necessary to determine the diagnostic value
of Ussing chamber measurements on tissues from patients
presenting with pre/sub-clinical or atypical CF.
2.3. Limitations and pitfalls
Air bubbles should be removed from the perfusion
system before the experiment (including containers with
experimental solution and all tubing), as their dislodge-
ment into the perfusion system may build up in close
proximity of the tissue during experiments and interfere
with drug effects and/or bioelectric responses. Drifting of
agar bridges is another potential problem that results in
drifting baseline values for Vte and Isc. After proper
equilibration of agar bridges baseline Vte and Isc are
typically very stable over the time course of the experi-
ment. Good tissue viability is critical for quantitative
assessment of bioelectric responses and is best maintained
by storing tissues on ice in an appropriate medium (for
details see Ref. [11]) and by proceeding with functional
measurements immediately. Tissue viability is more lim-
ited and the magnitude of bioelectric responses attenuated,
when tissues are stored at room temperature or in the
absence of nutrients. Another important parameter deter-
mining the magnitude of bioelectric responses is edge
leakage. To minimize edge damage, we mount tissues
under a stereomicroscope allowing for optimal orientation
of the small tissue specimen over the chamber opening
and preventing tissue damage during manipulation with
instruments. Typically, we perform experiments under
open-circuit conditions, which resemble the in vivo situ-
ation more closely than short-circuit conditions [12]. This
approach may contribute to longer viability and a larger
magnitude of drug responses. To control for sample-to-
sample variability of ex vivo tissue specimens, we gen-
erally perform diagnostic bioelectric measurements on
several biopsies per individual, and average data to obtain
a single mean value for each subject.
CFTR carries both cAMP-dependent and Ca2 +-activat-
ed Cl secretion in human intestinal epithelium [6,8,9,13].
Some investigators rely primarily on Ca2 +-mediated
responses, e.g., induced by carbachol (CCH) or histamine,
rather than cAMP-induced responses, to assess for CFTR-
mediated Cl secretion [14,15]. However, the analysis and
interpretation of Ca2 +-mediated responses is complicated
by the fact that Ca2 +-mediated agonists are also potent
activators of luminal K+ secretion. Therefore, it has been
suggested to express the magnitude of Cl secretion as a
Fig. 1. Ussing chamber analysis of human rectal biopsies. Original recordings of cholinergic (CCH, 100 Amol/l, basolateral) and cAMP-dependent (IBMX/
forskolin, 100/1 Amol/l, basolateral) activation of ion transport in (A) normal (non-CF) and (B) CF (F508del/F508del) rectal epithelia. Vte is plotted as a
function of time. The pulse amplitudes reflect the Rte and are caused by pulsed current injection. Experiments were performed in the presence of amiloride (10
Amol/l, luminal). (A) In non-CF tissue, CCH initially causes a lumen-negative Vte deflection that is augmented in the presence of IBMX/forskolin. IBMX/
forskolin, by increasing cytosolic cAMP, also induces a lumen-negative change in Vte, which corresponds to transepithelial Cl
 secretion. Therefore, cAMP-
dependent and cholinergic activation enhance Cl secretion cooperatively. After incubation with indomethacin and in the absence of IBMX/forskolin, CCH
causes a lumen-positive response, corresponding to K+ secretion. (B) In CF tissue, CCH induces lumen-positive deflections (K+ secretion) in the absence and
presence of cAMP-dependent stimulation, and cAMP-dependent stimulation with IBMX/forskolin does not change Vte, i.e., does not induce Cl
 secretion.
Reprinted with permission from Ref. [9].
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deflection) and K+ secretion (lumen-positive deflection).
However, this calculation does not take into account that
the magnitude of K+ secretion may be regulated indepen-
dently from CFTR, e.g., by hormonal regulation, and thusTable 2
Normal values (non-CF) and typical alterations of bioelectric responses in
CF rectal biopsies (as obtained in previous studies, as referenced)
Non-CF CF Ref.
DIsc-Amiloride 6.5F 1.2 AA/cm2 19.1F 3.7 AA/cm2 [5]
DIsc-IBMX/forskolin  43.2F 6.1 AA/cm2 + 8.2F 2.3 AA/cm2 [6]
DIsc-IBMX/forskolin + CCH  108.2F 13.7 AA/cm2 + 21.3F 6.2 AA/cm2 [6]
DIsc: change in equivalent short-circuit current. Data are shown as
meanF S.E.M.vary between individuals. Furthermore, assessment of
CFTR function by cholinergic activation in the presence
of indomethacin [14,15] may result in a K+ secretory
response in non-CF tissues [6,8,13] and thus produce false
positive results when used as a diagnostic test to establish
or refute a diagnosis of CF. We therefore use the magni-
tude of cAMP-mediated responses as the primary read out
of CFTR function. Agonists increasing cytosolic cAMP
(e.g., IBMX and forskolin) induce large and sustained Cl
secretory responses in non-CF tissues, and cAMP-depen-
dent Cl secretion is typically defective in CF tissues.
Cholinergic co-activation increases the driving force for
CFTR-mediated Cl secretion and may be of value in
determining low levels of residual function of mutant
CFTR.
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